In 2023, investigators also published the SPOTLIGHT trial [13], a randomized phase III trial also involving CLDN18.2-positive (≥75% of tumor cells with moderate-to-strong CLDN18 membranous staining), HER2-negative, locally advanced unresectable, or metastatic gastric/GEJ adenocarcinoma patients. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.